['advanced solid tumors']
['lurbinectedin (pm01183)', 'cisplatin']

        Inclusion Criteria:

          -  Voluntarily signed written informed consent

          -  Age ≥ 18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1.

          -  Life expectancy ≥ 3 months.

          -  Patients with confirmed diagnosis of advanced solid tumors.

          -  Patients may have received ≤ 2 chemotherapy-containing lines in the advanced setting.

          -  Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ seven days
             before inclusion in the study)

          -  Recovery or stabilization to grade ≤ 1 from any adverse event derived from previous
             treatment (up to grade 2 alopecia or asthenia/fatigue are allowed).

          -  No clinically significant changes in ECG.

          -  At least four weeks since the last monoclonal antibody containing therapy or
             definitive radiotherapy (RT)

          -  At least two weeks since the last biological/investigational single-agent therapy
             (excluding MAbs) and/or palliative RT (≤10 fractions or ≤30 Gy total dose)

          -  Fertil women must have pregnancy excluded by appropriate testing before study entry

        Exclusion Criteria:

          -  Prior treatment with PM01183 or trabectedin.

          -  Concomitant diseases/conditions:

               -  History within the last year or presence of unstable angina, myocardial
                  infarction, congestive heart failure, or clinically relevant valvular heart
                  disease or symptomatic arrhythmia or any asymptomatic ventricular arrhythmia
                  requiring ongoing treatment.

               -  Ongoing, non-neoplastic, chronically active liver disease of any origin.

               -  Active infection.

               -  Patients who are requiring any ongoing oxygen support.

               -  Known human immunodeficiency virus (HIV) infection.

               -  Any other major illness.

          -  Symptomatic or corticosteroid-requiring brain metastases or leptomeningeal disease
             involvement. Patients with asymptomatic documented stable brain metastases not
             requiring corticosteroids during the last three months are allowed.

          -  Peripheral sensory/motor neuropathy grade >1. Hearing impairment grade >1.

          -  Fertile men or women not using an effective method of contraception.

          -  History of bone marrow or stem cell transplantation

          -  Radiotherapye to >35% of the bone marrow.
      